NCT05132907View on ClinicalTrials.gov

Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

November 21, 2023

Study Completion Date

May 30, 2024

Conditions
SARS-CoV2 Infection
Interventions
BIOLOGICAL

HDT-301

HDT-301 Investigational Vaccine (a Nanoparticle Carrier-Formulated Replicon RNA (repRNA-CoV2S))

Trial Locations (1)

98057

Rainier Clinical Research, Renton

Sponsors

Lead Sponsor

HDT Bio

Collaborators (1)

C3 Research Associates
All Listed Sponsors
collaborator

Rainier Clinical Research Center

OTHER

collaborator

C3 Research Associates

UNKNOWN

lead

HDT Bio

INDUSTRY

NCT05132907 - Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein | Biotech Hunter | Biotech Hunter